Chemotherapy-Induced Neutropenia Treatment Market
Global Chemotherapy-Induced Neutropenia Treatment Market Size, Share & Trends Analysis Report by Therapy Type (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Transfusion, and Others), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global chemotherapy-induced neutropenia treatment market is anticipated to grow at a significant CAGR during the forecast period. Chemotherapy-induced neutropenia is a side effect of malignancy that affects the bone marrow directly. Patients with chemotherapy-induced neutropenia must be admitted to the hospital. In addition, the cost of treatment rises as the anti-infective treatment is used. The expanding usage of chemotherapy for cancer treatment, together with the rising prevalence of cancer around the world, is the primary driver of market expansion.
According to the National Cancer Institute (NCI), 1,806,590 new cancer cases will be identified in the United States in 2020, with a mortality rate of 606,520 people. Breast cancer, lung and bronchus cancer, and leukaemia, among others, are the most frequent cancers. Prostate, lung, and colorectal cancers will account for around 43% of all cancer diagnoses in males, while breast, lung, and colorectal cancers will account for approximately 50% of all new cancer diagnoses in women in 2020.
Impact of COVID-19 on Global Chemotherapy-Induced Neutropenia Treatment Market
The COVID-19 had impacted the global chemotherapy-induced neutropenia treatment market significantly owning to the lockdown in most of the nations to control the spread of the virus. Due to lockdown in several areas, the cancer screening of patients could not be done which caused higher tumour burdens and delay in effective treatment of cancer malignancies. As an outcome, the cancer mortality rate increased significantly. For instance, the impact of the COVID-19 in the first six months on breast cancer mortality in the United States has been projected to be 0.5% greater by 2030 than it would have been in the absence of the virus.
Segmental Outlook
The global chemotherapy-induced neutropenia treatment market is segmented based on the therapy type and distribution channel. Based on the type, the market is sub-segmented into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, splenectomy procedure, and others. Based on the distribution channel, the global chemotherapy-induced neutropenia treatment market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, colony-stimulating factor therapy is expected to propel the growth of the market, due to its ability to help bone marrow produce more white blood cells.
Global Chemotherapy-Induced Neutropenia Treatment Market Share by Therapy Type, 2021 (%)
The Colony-Stimulating Factor Therapy Segment is Anticipated to Hold a Prominent Share in the Global Chemotherapy-Induced Neutropenia Treatment Market
The colony-stimulating factor therapy segment holds the major market share and is anticipated to grow significantly during the forecast period in the global chemotherapy-induced neutropenia treatment market in the therapy type segment. One of the major reasons for other segments to hold a lesser market share is their inability to help bone marrow in producing white blood cells. For instance, in September 2021, Sino Biological developed high-activity CSF ligands and receptor proteins from many species to aid research into the biology of CSFs and receptors. G-CSF/CSF3 is a granulocyte colony-stimulating factor that activates all cells in the granulocyte lineage by binding to the homodimeric G-CSF receptor (G-CSFR/CD114). Neutropenia, acute myeloid leukaemia, and bone marrow transplants have all been associated with it.
Regional Outlooks
The global chemotherapy-induced neutropenia treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among the regions, the Asia-Pacific region in the global chemotherapy-Induced neutropenia treatment market is expected to hold a prominent market share due to the presence of several key market players.
Global Chemotherapy-Induced Neutropenia Treatment Market Growth, by Region 2022-2028
The Asia-Pacific Region is Estimated to Hold a Considerable Share in the Global Chemotherapy-Induced Neutropenia Treatment Market
The Asia-Pacific is anticipated to hold a considerable share in the market as the major players from countries falling under the Asia-Pacific region are showing significant growth in mergers and collaborations, and new product launches. For Instance, in December 2021, Lupin Pharmaceuticals, Inc. signed an agreement with Biomm SA for the distribution of Pegfilgrastim in Brazil. Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Additionally, the surge in government policies is now allowing many players to come into the market with their innovative products.
Market Players Outlook
The major companies serving the global chemotherapy-induced neutropenia treatment market include Amgen, Inc., Sanofi S.A., Novartis International AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2022, Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for LORVIQUA, as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global chemotherapy-induced neutropenia treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Chemotherapy-Induced Neutropenia Treatment Market
• Recovery Scenario of Global Chemotherapy-Induced Neutropenia Treatment Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Amgen Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. BeyondSpring Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Cellerant Therapeutics Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Kyowa Kirin Co. Ltd.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Mylan Pharmaceutical Pvt. Ltd.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Chemotherapy-Induced Neutropenia Treatment Market by Therapy Type
4.1.1. Antibiotic Therapy
4.1.2. Colony-Stimulating Factor Therapy
4.1.3. Granulocyte Transfusion
4.1.4. Splenectomy Procedure
4.1.5. Others
4.2. Global Chemotherapy-Induced Neutropenia Treatment Market by Distribution Channel
4.2.1. Hospital Pharmacy
4.2.2. Retail Pharmacy
4.2.3. Online Pharmacy
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Novartis AG
6.2. Partner Therapeutics Inc.
6.3. Pfizer Inc.
6.4. Spectrum Pharmaceuticals Inc.
6.5. Teva Pharmaceutical Industries Ltd.
6.6. Coherus Biosciences Inc.
1. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ANTIBIOTIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL COLONY-STIMULATING FACTOR CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL GRANULOCYTE TRANSFUSION CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL SPLENECTOMY PROCEDURE CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL OTHERS CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
8. GLOBAL HOSPITAL PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL RETAIL PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ONLINE PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
15. EUROPEAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
21. REST OF THE WORLD CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET, 2021-2028 (%)
4. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY THERAPY TYPE, 2021 VS 2027 (%)
5. GLOBAL ANTIBIOTIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL COLONY-STIMULATING FACTOR CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL GRANULOCYTE TRANSFUSION CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL SPLENECTOMY PROCEDURE CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL OTHERS CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
11. GLOBAL HOSPITAL PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL RETAIL PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL ONLINE PHARMACY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
17. UK CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF THE ASIA-PACIFIC CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD CHEMOTHERAPY-INDUCED NEUTROPENIA TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
